Ectodysplasin A2 Receptor antibody

Catalog No. ABIN6990649

Product Details anti-Ectodysplasin A2 Receptor Antibody

Target: Ectodysplasin A2 Receptor (EDA2R)

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Ectodysplasin A2 Receptor antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Purification: XEDAR Antibody is affinity chromatography purified via peptide column.

Immunogen: XEDAR antibody was raised against recombinant human XEDAR.

Isotype: IgG

Application Details

Application Notes: XEDAR antibody can be used for the detection of XEDAR by Western blot at 0.5 - 2 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 10 μ,g/mL.

Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: XEDAR Antibody is supplied in PBS containing 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,4 °C

Storage Comment: XEDAR antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Target Details for Ectodysplasin A2 Receptor

Target: Ectodysplasin A2 Receptor (EDA2R)

Alternative Name: XEDAR (EDA2R Products)

Synonyms: EDA-A2R antibody, EDAA2R antibody, TNFRSF27 antibody, XEDAR antibody, 9430060M22Rik antibody, Xedar antibody, RGD1564025 antibody, ectodysplasin A2 receptor antibody, EDA2R antibody, Eda2r antibody

Background: XEDAR Antibody: X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2). Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain. Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-κ,B and JNK pathways. Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis. The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment.

Gene ID: 60401

UniProt: Q9HAV5